ARTL is expected to report earnings to rise 156.20% to -89 cents per share on March 26
Q4'24
Est.
$-0.90
Q3'24
Beat
by $0.44
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.13
Q4'23
Missed
by $0.43
The last earnings report on November 12 showed earnings per share of -34 cents, beating the estimate of -79 cents. With 46.61K shares outstanding, the current market capitalization sits at 3.29M.
a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system.